EZH2 and lymphoma: Such inhibitors demonstratedHMTase-dependent activities both in vitro and in vivo, and some of them (CPI-1205, SHR2554, DS-3201b,CPI-0209) are presently undergoing phase I/II clinical investigationsfor solid or hematological tumors, as deeply discussed in recent reviews.45−47 Notably, 2020 saw the FDA-approval of the first SAM-competitiveanti-EZH2 drug, EPZ-6438 or tazemetostat (Tazverik), which has beenauthorized for the care of locally advanced epithelioid sarcoma andfollicular lymphoma.48−50 An overview of the EZH2 inhibitors currently in clinicaltrials is reported in Figure 1.